[HTML][HTML] Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR
…, M Ando, H Miyazawa, T Tanaka, Y Saijo… - … England Journal of …, 2010 - Mass Medical Soc
Background Non–small-cell lung cancer with sensitive mutations of the epidermal growth
factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib…
factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib…
[PDF][PDF] First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for …
…, S Okinaga, I Mikami, M Ando, K Yamazaki, Y Saijo… - J Clin …, 2009 - researchgate.net
Purpose This multicenter phase II study was undertaken to investigate the efficacy and
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) harboring …
feasibility of gefitinib for patients with advanced non–small-cell lung cancer (NSCLC) harboring …
[PDF][PDF] Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene …
…, Y Kimura, N Morikawa, H Watanabe, Y Saijo… - J Clin …, 2006 - researchgate.net
… Akira Inoue, Takuji Suzuki, Tatsuro Fukuhara, Makoto Maemondo, Yuichiro Kimura, Naoto
Morikawa, Hiroshi Watanabe, Yasuo Saijo, and Toshihiro Nukiwa … Financial support: Yasuo …
Morikawa, Hiroshi Watanabe, Yasuo Saijo, and Toshihiro Nukiwa … Financial support: Yasuo …
Severe acute interstitial pneumonia and gefitinib
A Inoue, Y Saijo, M Maemondo, K Gomi, Y Tokue… - The Lancet, 2003 - thelancet.com
Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase
that is an effective treatment for patients with advanced non-small cell lung cancer who do …
that is an effective treatment for patients with advanced non-small cell lung cancer who do …
[HTML][HTML] Infiltration of COX-2–expressing macrophages is a prerequisite for IL-1β–induced neovascularization and tumor growth
…, S Hamano, K Sonoda, Y Saijo… - The Journal of …, 2005 - Am Soc Clin Investig
Inflammatory angiogenesis is a critical process in tumor progression and other diseases. The
inflammatory cytokine IL-1β promotes angiogenesis, tumor growth, and metastasis, but its …
inflammatory cytokine IL-1β promotes angiogenesis, tumor growth, and metastasis, but its …
Proinflammatory cytokine IL-1β promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction
Y Saijo, M Tanaka, M Miki, K Usui, T Suzuki… - The Journal of …, 2002 - journals.aai.org
Inflammatory conditions are associated with tumor development. IL-1β is a multifunctional
and proinflammatory cytokine that affects nearly all types of cells. To investigate the role of IL-…
and proinflammatory cytokine that affects nearly all types of cells. To investigate the role of IL-…
[HTML][HTML] Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization
…, J Itoh, A Umezawa, H Kijima, S Fukuda, Y Saijo - Molecular …, 2011 - Springer
Mesenchymal stromal cells (MSCs), also called mesenchymal stem cells, migrate and function
as stromal cells in tumor tissues. The effects of MSCs on tumor growth are controversial. …
as stromal cells in tumor tissues. The effects of MSCs on tumor growth are controversial. …
[PDF][PDF] Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group …
…, H Yokouchi, H Watanabe, T Tsukamoto, Y Saijo… - J Clin Oncol, 2008 - academia.edu
Purpose Amrubicin, a new anthracycline agent, and topotecan are both active for previously
treated small-cell lung cancer (SCLC). No comparative study of these agents has been …
treated small-cell lung cancer (SCLC). No comparative study of these agents has been …
[HTML][HTML] Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model
…, H Xin, M Kanehira, R Sun, T Nukiwa, Y Saijo - Molecular Therapy, 2011 - cell.com
Multipotent stromal cells (MSCs) ameliorate several types of lung injury. The differentiation
of MSCs into specific cells at the injury site has been considered as the important process in …
of MSCs into specific cells at the injury site has been considered as the important process in …
[HTML][HTML] Methylation of the KEAP1 gene promoter region in human colorectal cancer
…, H Kijima, J Mimura, K Itoh, S Fukuda, Y Saijo - BMC cancer, 2012 - Springer
Background The Keap1-Nrf2 pathway has been reported to be impaired in several cancers.
However, the status of Keap1-Nrf2 system in human colorectal cancer (CRC) has not been …
However, the status of Keap1-Nrf2 system in human colorectal cancer (CRC) has not been …